Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Background: Glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are the main incretin hormones, and be responsible for the insulinotropic incretin effect. The addition of a GIP agonist to a GLP-1agonist has been hypothesized to significantly potentiate the weight-losing and glycemia control effect, which might offer a new therapeutic option in the treatment of type 2 diabetes. The current meta-analysis aims to synthesize evidence of primary efficacy and safety outcomes through clinically randomized controlled trials to evaluate integrated potency and signaling properties. Method: We conducted comprehensive literature searches in Cochrane Library, Web of Science, Embase and PubMed for relevant literatures investigating the efficacy and/or safety of Tirzepatide published in the English as of May 30, 2023 was retrieved. We synthesized results using standardized mean differences (SMDs) and 95% confidence intervals (95 CIs) for continuous outcomes, and odds ratios (ORs) along with 95 Cis for dichotomous outcomes. All analyses were done using Revman version 5.3, STATA version 15.1 and the statistical package ‘meta’. Results: Participants treated with weekly Tirzepatide achieved HbA1c and body weight target values significantly lower than any other comparator without clinically significant increase in the incidence of hypoglycemic events, serious and all-cause fatal adverse events. However, gastrointestinal adverse events and decreased appetite events were reported more frequently with Tirzepatide treatment than with placebo/controls. Conclusion: The Tirzepatide, a dual GIP/GLP-1 receptor co-agonist, for diabetes therapy has opened a new era on personalized glycemia control and weight loss in a safe manner with broad and promising clinical implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Asmar, M., Asmar, A., Simonsen, L., Holst, J. J., & Bülow, J. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00389 · Cited by 4
RetractedThe PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
(2000) · Cited by 9,198
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“Type 2 diabetes (T2D) is a chronic metabolic condition marked by hyperglycaemia that requires stepwise addition of multiple glucose-lowering medications as the disease progression [1, 2].”
BackgroundTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095 · cited 1×
“Although this compound with subcutaneous injection weekly have achieved unprecedented results in glucose control and weight loss employed in many clinical trials, the quantities may significantly change the potential pathogenesis of T2D [54] and is related to the remission of diabetes [55, 56].”
BackgroundA role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Lean, M. E. J., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30068-3 · Cited by 1,017 · cited 1×
“Although this compound with subcutaneous injection weekly have achieved unprecedented results in glucose control and weight loss employed in many clinical trials, the quantities may significantly change the potential pathogenesis of T2D [54] and is related to the remission of diabetes [55, 56].”
Background
Research works printed but not linked: 1
- Targets G. Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S73-s84.
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
AI-Driven Polypharmacology in Small-Molecule Drug Discovery
Abdelsayed, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146996 · Cited by 70
Rising tide: The global surge of type 2 diabetes in children and adolescents demands action now
Pappachan, J. M., Fernandez, C. J., & Ashraf, A. P. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i5.797 · Cited by 69
The Rise of Type 2 Diabetes in Children and Adolescents: An Emerging Pandemic
Goyal, S., & Vanita, V. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70029 · Cited by 48
Liu, Z., Yu, S., Jin, X., Sheng, L., Rouzi, M. R. Y., Gao, J., Lü, J., & Lei, T. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s559919 · Cited by 34
Metadata
- Authors
- Zhou, Q., Lei, X., Fu, S., Liu, P., Long, C., Wang, Y., Li, Z., Xie, Q., & Chen, Q.
- Affiliations
- Chengdu University of Traditional Chinese Medicine (CN)
- Ya'an Polytechnic College (CN)
- Sichuan Integrative Medicine Hosipital (CN)
- Corresponding author
- Chen, Qiu
- Venue
- Diabetology & Metabolic Syndrome
- Published
- 2023-10-30
- Volume
- 15
- Issue
- 1
- Pages
- 222-222
- ISSN
- 1758-5996 (ISSN-L)
- PMC
- PMC10614386
- OpenAlex
- W4388034622
- Cited by
- 55
- References
- 64
- Citations by year
- 2026: 18 · 2025: 26 · 2024: 10 · 2023: 1
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Diabetology & Metabolic Syndrome (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- tirzepatide, type 2 diabetes, GLP-1 receptor agonists, GIP receptor agonist, GIP/GLP-1 receptor agonist, incretin-based therapy, glycemic control, HbA1c, weight loss, hypoglycemia, gastrointestinal adverse effects, appetite loss, drug safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1186/s13098-023-01198-4
- The paper
- Zhou, Q., Lei, X., Fu, S., Liu, P., Long, C., Wang, Y., Li, Z., Xie, Q., & Chen, Q. (2023). Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetology & Metabolic Syndrome. https://doi.org/10.1186/s13098-023-01198-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.